CD19 CAR-T cell therapy (Novartis)

CAR.CD19-T refers to a class of cellular immunotherapies consisting of T cells genetically engineered to express a chimeric antigen receptor (CAR) specific for the CD19 antigen. CD19 is a transmembrane protein widely expressed on the surface of B-lineage cells, making it a primary target for treating B-cell malignancies such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and various B-cell non-Hodgkin lymphomas. The CAR construct typically incorporates an extracellular antigen-binding domain (often a single-chain variable fragment or scFv), a hinge and transmembrane region, and intracellular signaling domains, including the CD3-zeta chain and a co-stimulatory domain (most commonly CD28 or 4-1BB). Upon binding to CD19 on target cells, the CAR-T cells undergo activation, proliferation, and exert cytotoxic activity against the malignant B cells. Several CD19-directed CAR-T products have received regulatory approval, including tisagenlecleucel and axicabtagene ciloleucel. In research settings, CAR.CD19-T cells are frequently employed as a benchmark or negative control for evaluating the specificity and efficacy of novel CAR-T therapies targeting other antigens.